It is noteworthy that the increased risk of hyperbilirubinemia is caused by nilotinib, because it inhibits human uridine diphosphate-glucuronosyltransferase (UGT1A1) activity. This evidence concerns the gene UGT1A1 and Hyperbilirubinemia.